Rubraca® (rucaparib) – New indication
April 6, 2018 - Clovis Oncology announced the FDA approval of Rubraca (rucaparib) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Top